Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

TAK-329 Glucose Clamp Study

Phase 1

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: TAK-329
Drug: Insulin
Drug: Placebo

First Posted Date: 2011-03-09

Last Posted Date: 2012-02-13

Lead Sponsor: Takeda

Target Recruit Count: 37

Registration Number: NCT01311076

Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease

Phase 3

Completed

Conditions: Safety

Interventions: Drug: Olmesartan medoxomil and hydrochlorothiazide
Drug: Azilsartan medoxomil and chlorthalidone

First Posted Date: 2011-03-07

Last Posted Date: 2013-12-13

Lead Sponsor: Takeda

Target Recruit Count: 153

Registration Number: NCT01309828

Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Vortioxetine
Drug: Placebo

First Posted Date: 2011-02-18

Last Posted Date: 2013-12-13

Lead Sponsor: Takeda

Target Recruit Count: 17

Registration Number: NCT01299805

Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo to alogliptin
Drug: Alogliptin
Drug: Metformin
Drug: Pioglitazone

First Posted Date: 2011-02-03

Last Posted Date: 2013-03-22

Lead Sponsor: Takeda

Target Recruit Count: 506

Registration Number: NCT01289119

Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension

Phase 2

Completed

Conditions: Essential Hypertension

Interventions: Drug: Placebo
Drug: Azilsartan
Drug: Candesartan cilexetil

First Posted Date: 2011-02-03

Last Posted Date: 2011-02-03

Lead Sponsor: Takeda

Target Recruit Count: 926

Registration Number: NCT01289132

Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Alogliptin
Drug: Voglibose

First Posted Date: 2010-12-20

Last Posted Date: 2012-02-03

Lead Sponsor: Takeda

Target Recruit Count: 438

Registration Number: NCT01263496

Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Alogliptin
Drug: Voglibose

First Posted Date: 2010-12-20

Last Posted Date: 2012-02-03

Lead Sponsor: Takeda

Target Recruit Count: 480

Registration Number: NCT01263470

Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Alogliptin and voglibose

First Posted Date: 2010-12-20

Last Posted Date: 2012-02-03

Lead Sponsor: Takeda

Target Recruit Count: 179

Registration Number: NCT01263509

Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Alogliptin and voglibose
Drug: Voglibose

First Posted Date: 2010-12-20

Last Posted Date: 2012-02-03

Lead Sponsor: Takeda

Target Recruit Count: 230

Registration Number: NCT01263483

Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder

Phase 2

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: Placebo
Drug: Vortioxetine

First Posted Date: 2010-12-07

Last Posted Date: 2013-12-18

Lead Sponsor: Takeda

Target Recruit Count: 600

Registration Number: NCT01255787

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy